AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9240873
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula (12.3 mg/l iron)
Trial: 9240873
Drug: Non-fortified formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fortified formula (1.4 mg/l iron)
Trial: 29946728
Drug: Fruquintinib 5
RxNorm normalized name: fruquintinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5 mg orally once daily for 21 days followed by 7 days off in 28-day cycles (n=278)
Trial: 29946728
Drug: Fruquintinib 5
RxNorm normalized name: fruquintinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5 mg
Trial: 20639271
Drug: IFNbeta‐1a treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a treatment
Trial: 17998225
Drug: 300,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300,000 IU intramuscular vitamin D2 injection
Trial: 7808602
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Trial: 7808602
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Trial: 7808602
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Trial: 7808602
Drug: All dose
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dose groups (0.1 mg, 0.2 mg, 0.4 mg)
Trial: 25865175
Drug: Frequent self-weighing
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent self-weighing (daily or several times per week)
Trial: 23332012
Drug: soluble vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soluble vascular cell adhesion molecule (sVCAM)
Trial: 23332012
Drug: tumour necrosis
RxNorm normalized name: Tumour necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tumour necrosis factor-α receptor-I (TNFR-I)
Trial: 17204967
Drug: Micronutrient sprinkles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient sprinkles (MMN) containing iron 12.5 mg + folic acid 150 microg + zinc 5 mg + vitamins A, C and D3
Trial: 17204967
Drug: Iron/folate sprinkles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron/folate sprinkles (iron 12.5 mg + folic acid 150 microg)
Trial: 15171476
Drug: deltaBV/UF ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deltaBV/UF ratio of less than 2.6%/L
Trial: 11369149
Drug: Self-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment group (n=123)
Trial: 11369149
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (self-treatment and active control)
Trial: 9260599
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg orally twice a day
Trial: 9260599
Drug: Ondansetron suppository
RxNorm normalized name: ondansetron Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron suppository 16 mg once daily
Trial: 23572341
Drug: 30% inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% inhaled xenon for 24 h combined with 72 h of moderate systemic hypothermia
Trial: 19066383
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly weigh-ins)
Trial: 8893656
Drug: Benzodiazepine (mini
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine (mini doses)
Trial: 6391442
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol hydrochloride 0.5% every 12 hours
Trial: 6391442
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol hydrochloride 0.5% every 12 hours with oral acetazolamide 500 mg every 12 hours
Trial: 6391442
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide 500 mg every 12 hours
Trial: 6391442
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide 500 mg every 12 hours with topical betaxolol
Trial: 31733455
Drug: S-Adenosyl-Methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Adenosyl-Methionine (SAMe) 3,200 mg/day
Trial: 23910908
Drug: Gastric acid
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric acid suppressive medications (AS)
Trial: 21477068
Drug: Salbutamol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (6 mg)
Trial: 19678813
Drug: 5‐ASA‐MMX (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA‐MMX (2.4 g/day, once daily)
Trial: 19678813
Drug: Asacol (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol (2.4 g/day, twice daily)
Trial: 17197641
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg/day; NSAID)
Trial: 2171595
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy (40 Gy in the chest tumour)
Trial: 350496
Drug: Co-trimoxazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (6 mg trimethoprim plus 30 mg sulphamethoxazole/kg)
Trial: 350496
Drug: Streptomycin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin (50 mg/kg)
Trial: 350496
Drug: Neomycin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin (50 mg/kg)
Trial: 7036289
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (chemotherapy, immunotherapy, and chemoimmunotherapy)
Trial: 22315328
Drug: Ropivacaine 1
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1 ml kg(‐1) 0.2% or 0.35% at an injection speed of 0.25 ml s(‐1)
Trial: 22315328
Drug: Ropivacaine 1
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1 ml kg(‐1) 0.2% or 0.35% at an injection speed of 0.5 ml s(‐1)
Trial: 19822404
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium patch
Trial: 19822404
Drug: Control (menthol)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (menthol) patch
Trial: 17601378
Drug: ACEI/ATRA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ATRA therapy for 62+/−5 months
Trial: 17601378
Drug: ACEI/ATRA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ATRA therapy for 62+/−5 months among patients with genotype II
Trial: 17601378
Drug: ACEI/ATRA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ATRA therapy
Trial: 11519502
Drug: Metronidazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (two 2-g doses, 48 hours apart, repeated at 24 to 29 weeks)
Trial: 11519502
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two doses, 48 hours apart, repeated at 24 to 29 weeks)
Trial: 9285463
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg/day) and levodopa
Trial: 9285463
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of selegiline
Trial: 8289134
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg daily oral doses
Trial: 8289134
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg daily oral doses
Trial: 8289134
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg daily oral doses
Trial: 2951449
Drug: rHBsAg vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHBsAg vaccine (20 micrograms intramuscular dose)
Trial: 2951449
Drug: HEPTAVAX-B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEPTAVAX-B vaccine (plasma-derived)
Trial: 28294694
Drug: Intraoral Low-Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoral Low-Level Laser Therapy (LLLT)
Trial: 28294694
Drug: Transcutaneous Low-Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous Low-Level Laser Therapy (LLLT)
Trial: 27260639
Drug: Plaster cast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plaster cast treatment (immobilisation in a below elbow cast for 6 to 10 weeks)
Trial: 27260639
Drug: Immediate surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate surgical fixation (using preferred technique and implant)
Trial: 27260639
Drug: Plaster cast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plaster cast treatment
Trial: 22100058
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day plus ezetimibe 10 mg/day
Trial: 17956583
Drug: Cyclophosphamide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (single intravenous infusion)
Trial: 17956583
Drug: Intratumoral bacille
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral bacille Calmette‐Guérin (BCG) immunotherapy
Trial: 15899957
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion during hyperglycemic clamp (7 mm)
Trial: 15899957
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion during hyperglycemic clamp (7 mm)
Trial: 17223419
Drug: Postprocedural heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprocedural heparin (n = 758; median duration 2 days)
Trial: 17223419
Drug: Postprocedural heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprocedural heparin (n = 758)
Trial: 17223419
Drug: Postprocedural heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprocedural heparin (n = 555)
Trial: 8592662
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose studies of immediate release products
Trial: 8592662
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose studies of immediate release products
Trial: 8592662
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose studies of sustained release products
Trial: 8592662
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose studies of sustained release products
Trial: 8592662
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose studies
Trial: 8592662
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose studies
Trial: 1136854
Drug: Theophyllamine (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophyllamine (as the only active drug)
Trial: 30907035
Drug: Neiguan point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neiguan point acupuncture combined with amiodarone therapy
Trial: 30907035
Drug: Amiodarone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone therapy alone
Trial: 18259856
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to ovarian function suppression/ablation (OFS) and 5 years of tamoxifen
Trial: 15875528
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 microg once daily
Trial: 12765916
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 200 microg twice daily
Trial: 15283939
Drug: Dydrogesterone (DYD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (DYD; 10 mg per day)
Trial: 15283939
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA; 10 mg per day)
Trial: 15283939
Drug: Nomegestrol acetate
RxNorm normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Nomegestrol acetate (NMG; 5 mg per day)
Trial: 15283939
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate (NETA; 10 mg per day)
Trial: 11694700
Drug: Intramuscular benzathine
RxNorm normalized name: Cephapirin Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular benzathine penicillin G (BPG)
Trial: 6869040
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy (n = 12)
Trial: 6869040
Drug: Small group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small group therapy (n = 11)
Trial: 6869040
Drug: Large group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large group therapy (n = 11)
Trial: 28728602
Drug: Enhanced upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced upper limb therapy for 45 min, three times/week for 12 weeks
Trial: 10403069
Drug: Rizatriptan 10-mg
RxNorm normalized name: rizatriptan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 10-mg wafer
Trial: 10403069
Drug: Rizatriptan 5-mg
RxNorm normalized name: rizatriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 5-mg wafer
Trial: 8024907
Drug: 1% etidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% etidocaine 10 ml
Trial: 8024907
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution 10 ml
Trial: 798110
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment (6 mg of stanozolol per day)
Trial: 28394217
Drug: Control Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Exposure Therapy (CET)
Trial: 23517508
Drug: Nadroparin 2850
RxNorm normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 2850 IU/0.3 ml subcutaneously once a day for 12 months
Trial: 23517508
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment alone (control group)
Trial: 23517508
Drug: Nadroparin treatment
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin treatment in older patients
Trial: 16931656
Drug: Large-dose propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Large-dose propofol (Group HiP)
Trial: 10632646
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg once daily, plus clarithromycin 250 mg and metronidazole 400 mg twice daily
Trial: 10632646
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg twice daily, plus clarithromycin 250 mg and metronidazole 400 mg twice daily
Trial: 12060043
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg once daily
Trial: 10632646
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg twice daily
Trial: 2762658
Drug: Indobufen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (400 mg/die)
Trial: 8020032
Drug: Warfarin (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (oral, INR 2.0-3.5)
Trial: 25546465
Drug: ASA 81
RxNorm normalized name: ASA 81 MG Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 81 mg once-daily
Trial: 25546465
Drug: ASA 325
RxNorm normalized name: ASA 325 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 325 mg once-daily
Trial: 25546465
Drug: ASA 81
RxNorm normalized name: ASA 81 MG Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 81 mg four times daily
Trial: 23324310
Drug: MDA measured
RxNorm normalized name: BK-MDA
DrugBank: BK-MDA (DB12809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDA measured in septic rats after intraperitoneal injection of MDR Pseudomonas aeruginosa
Trial: 18576334
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg twice weekly plus weekly methotrexate (MTX; > or =15 mg)
Trial: 18576334
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once weekly plus weekly methotrexate (MTX; > or =15 mg) plus placebo
Trial: 16490020
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (Viagra), flexible-dose (25 mg, 50 mg, or 100 mg) for 10 weeks
Trial: 11111392
Drug: ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine plus antibiotics
Trial: 11111392
Drug: bismuth plus
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bismuth plus antibiotics
Trial: 9179631
Drug: Citalopram (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (adjuvant selective serotonin reuptake inhibitor)
Trial: 8473405
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GIP and GLP-1
Trial: 8473405
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of GLP-1 (0.15 pmol/kg.min)
Trial: 25946576
Drug: Carbetocin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (single IV dose)
Trial: 25946576
Drug: Oxytocin (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (IV infusion)
Trial: 25437032
Drug: Standard multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multivitamin supplement (sMVS) - contains approximately 100% of the recommended daily allowance (RDA) for iron, vitamin B12, and folic acid
Trial: 16030050
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1000 mg bid for 1 year
Trial: 10543488
Drug: 300 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 U/kg of heparin
Trial: 10543488
Drug: 150 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 U/kg of heparin
Trial: 2286595
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg once daily
Trial: 9309373
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg twice daily
Trial: 2029814
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and rectal thermometers
Trial: 35824
Drug: salazosulphapyridine (SASP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salazosulphapyridine (SASP) 1 g X 3
Trial: 35824
Drug: methyl-salazosulphapyridine (methyl-SASP)
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyl-salazosulphapyridine (methyl-SASP) 125 mg x 3
Trial: 31818831
Drug: SMS intervention
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS intervention targeting adherence to cardiovascular medications
Trial: 28866264
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution 100ml/h for 3 days
Trial: 28866264
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous fluid
Trial: 23958184
Drug: Usual post-treatment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Usual post-treatment care (control group)
Trial: 21377071
Drug: IV lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV lornoxicam 16 mg